Inovio Pharmaceuticals Inc (INO): Inovio Achieves Third Cancer Indication...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	113
Posts	25553
Boards Moderated	4
Alias Born	02/01/2004

Ubertino

Re: None

Monday, 04/08/2019 10:20:44 AM

Monday, April 08, 2019 10:20:44 AM

Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

PLYMOUTH MEETING, Pa., April 8, 2019 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3112) in combination with durvalumab targeting cervical, anal, penile, and vulvar cancers associated with the human papilloma virus (HPV). The milestone achievement for this multi-indication trial is the third MEDI0457-related Phase 2 milestone from AstraZeneca; two previous milestone payments resulted from initiating Phase 2 combination trials targeting head and neck and cervical cancers. Financial arrangements were not disclosed.
.....

https://www.prnewswire.com/news-releases/inovio-achieves-third-cancer-indication-milestone-for-medi0457-phase-2-development-300825576.html